0.02% Topical Dutasteride UK: Low Dose Hair Loss Treatment
Topical dutasteride 0.02% is a lower-concentration scalp-applied dutasteride formulation that has now been directly studied in men with androgenetic alopecia.
A 2025 Phase II clinical trial tested 0.01%, 0.02% and 0.05% topical dutasteride over 24 weeks. The study provides specific human evidence for 0.02% as part of a dose-ranging topical dutasteride pathway, while also showing why concentration should not be interpreted as a simple “higher is always better” scale.
Looking for the main topical dutasteride guide?
This page focuses specifically on the 0.02% concentration. For the broader mechanism, evidence, safety information and comparison with topical finasteride, visit our main Topical Dutasteride UK guide.
What Is 0.02% Topical Dutasteride?
A 0.02% topical dutasteride solution contains 0.2 mg of dutasteride per mL. In the 2025 Phase II trial, participants in the 0.02% arm applied 1 mL once daily to a defined scalp treatment area for 24 weeks.
Why Are People Interested in 0.02% Topical Dutasteride?
The main attraction of a lower topical concentration is not that it can be assumed to be risk-free. It is that treatment strength can be considered more deliberately rather than automatically choosing the highest concentration available.
Lower concentration than 0.05%
At the same application volume, a 0.02% solution contains less dutasteride than a 0.05% solution. That makes it a distinct dose option rather than simply another label for the same formulation.
It has been studied in humans
Unlike many arbitrary compounded concentrations, 0.02% was specifically included in the 2025 randomized Phase II topical dutasteride trial.
Strength can be part of the treatment decision
The appropriate concentration depends on the whole treatment strategy, including diagnosis, previous treatment, application amount, formulation and clinical suitability.
Does 0.02% Topical Dutasteride Work?
The strongest current evidence comes from a 2025 randomized, double-blind Phase II trial that studied topical dutasteride 0.01%, 0.02% and 0.05% alongside placebo and oral finasteride 1 mg.
What happened in the 0.02% group?
The 0.02% topical dutasteride group showed a statistically significant improvement from its own baseline in target-area hair count at week 24.
The least-squares mean change from baseline in target-area hair count was 27.48 in the 0.02% group at week 24.
However, the direct pairwise comparison between 0.02% and placebo for target-area hair count did not reach conventional statistical significance in that study. This distinction matters when interpreting the result.
Why this makes the 0.02% page more credible, not less
The correct interpretation is not that 0.02% has been proven to outperform placebo on every endpoint. It is that 0.02% was directly studied, showed meaningful within-group improvement, produced encouraging photographic and patient-reported findings, and sits within an emerging dose-ranging evidence base that still needs larger confirmatory trials.
What Did Patients and Investigators See at 0.02%?
The same Phase II study also included global photography and patient-reported hair assessments.
51.85% reached GPA ≥ +2
At week 24, 14 of 27 participants in the 0.02% group achieved an investigator global photography score of at least +2 in the study.
88.89% favourable questionnaire response
At week 24, 24 of 27 participants in the 0.02% group had the study-defined favourable MHGQ response for hair on top of the head.
27 of 27 met the study threshold
For the study’s overall-hair MHGQ question at week 24, all 27 participants in the 0.02% arm met the reported response threshold. This was a secondary patient-reported outcome and should not be interpreted as proof of universal clinical success.
0.01% vs 0.02% vs 0.05% Topical Dutasteride
All three concentrations were studied within the same 2025 Phase II programme, which gives a useful dose-ranging comparison. The clearest efficacy signal in the trial was seen with 0.05%, but that does not make 0.02% irrelevant as a personalised lower-strength option.
| Feature | 0.01% | 0.02% | 0.05% |
|---|---|---|---|
| Dutasteride per mL | 0.1 mg/mL | 0.2 mg/mL | 0.5 mg/mL |
| Studied in Phase II? | Yes | Yes | Yes |
| Week-24 hair-count change from baseline | 32.32 | 27.48 | 75.52 |
| Significantly better than placebo for hair count? | Yes in the reported pairwise analysis | No, pairwise p=0.0801 | Yes |
| Position in the evidence | Lowest studied concentration | Intermediate studied concentration | Strongest efficacy signal in this Phase II study |
| Best concentration? | The trial supports dose-ranging research but does not establish one concentration as appropriate for every patient. Treatment should be individualized. | ||
Does 0.02% Mean Lower Systemic Exposure?
It is reasonable to say that 0.02% contains less dutasteride per mL than 0.05%, but it is not appropriate to promise a specific reduction in systemic exposure from concentration alone.
In the Phase II study, the authors reported no statistically significant change from baseline in serum testosterone or DHT across the dutasteride-treated groups at weeks 12 and 24. Detailed pharmacokinetic analysis was reported specifically for the 0.05% formulation rather than establishing a separate pharmacokinetic profile for 0.02%.
Lower concentration does not mean zero systemic risk
Actual exposure can depend on concentration, application volume, scalp area, vehicle, frequency and individual absorption. Dutasteride-related systemic adverse effects therefore cannot be excluded simply because the formulation is topical or lower strength.
0.02% Topical Dutasteride Side Effects and Safety
The 2025 Phase II study reported no adverse events, serious adverse events, deaths or withdrawals due to safety concerns during the study period. However, the sample size was small and treatment lasted 24 weeks, so this cannot establish long-term safety.
Scalp tolerability
- Local irritation remains possible with topical formulations
- Vehicle ingredients may influence tolerability
- Scalp condition and treated area can affect practical use
- One study cannot exclude less common reactions
Dutasteride safety still matters
- Systemic absorption can occur
- Sexual dysfunction should be discussed with a healthcare professional
- Current UK product information includes precautionary mood-related wording
- Pregnancy exposure requires particular caution
Is 0.05% Dutasteride Automatically Better Than 0.02%?
The 0.05% group produced the strongest efficacy signal in the 2025 Phase II trial. That is an important finding, but it does not mean every patient should automatically use the highest studied concentration.
Efficacy is only one factor
Treatment choice also needs to consider tolerability, delivered dose, previous treatment and individual clinical circumstances.
Concentration is not the whole dose
A topical concentration only tells you how much drug is present per unit volume. The amount applied and treated scalp area also influence the delivered dose.
Evidence is still developing
The topical dutasteride evidence base remains much smaller than the evidence supporting more established hair-loss treatments. Larger and longer trials are still needed.
0.02% Topical Dutasteride vs Topical Finasteride
Dutasteride and finasteride are both 5-alpha-reductase inhibitors, but dutasteride inhibits both type I and type II enzymes, while finasteride primarily inhibits type II.
The 2025 dutasteride study compared topical dutasteride with oral finasteride 1 mg, not topical finasteride. It therefore does not prove that 0.02% topical dutasteride is superior to topical finasteride.
Who Might Explore 0.02% Topical Dutasteride?
People exploring an intermediate studied concentration
0.02% sits between the 0.01% and 0.05% concentrations used in the Phase II trial and may be relevant when a lower-strength dutasteride route is being considered.
People specifically seeking scalp-applied treatment
Some users want to explore a topical DHT-focused route rather than a conventional oral 5-alpha-reductase inhibitor.
People who do not want a one-strength-fits-all approach
A personalised pathway allows the treatment concentration and wider formulation to be considered as part of the whole clinical plan.
Personalised Hair TreatmentExplore Related Topical Dutasteride and Hair Loss Guides
Explore 0.02% Topical Dutasteride and Other Hair Loss Options
Use the Hair Customiser to explore personalised topical hair-loss formulations and strengths. Selecting 0.02% dutasteride does not guarantee that it will be prescribed. Prescription-only treatment remains subject to clinical assessment and prescriber approval.
0.02% Topical Dutasteride UK FAQs
What is 0.02% topical dutasteride?
It is a scalp-applied dutasteride formulation containing 0.2 mg of dutasteride per mL. This concentration was directly evaluated in a 2025 Phase II clinical trial in men with androgenetic alopecia.
Has 0.02% topical dutasteride been clinically studied?
Yes. A randomized Phase II study included separate 0.01%, 0.02% and 0.05% topical dutasteride groups treated once daily for 24 weeks.
Did 0.02% topical dutasteride improve hair count?
In the Phase II study, the 0.02% group showed a statistically significant improvement in target-area hair count from its own baseline at week 24. However, its direct pairwise comparison with placebo for hair count did not meet the conventional p<0.05 threshold.
Is 0.02% dutasteride better than 0.05%?
The available Phase II trial does not support that conclusion. The 0.05% group produced the strongest efficacy signal in that study. The appropriate concentration still depends on the wider treatment plan and individual suitability.
Is 0.02% topical dutasteride safer than 0.05%?
A lower concentration contains less dutasteride per mL, but safety cannot be predicted from concentration alone. Application volume, vehicle, treated scalp area and individual absorption also affect exposure.
Does topical dutasteride affect serum DHT?
In the 2025 Phase II trial, the authors reported no statistically significant changes from baseline in serum testosterone or DHT across the dutasteride-treated groups at weeks 12 and 24. This does not mean systemic exposure is impossible.
Can 0.02% topical dutasteride cause sexual side effects?
Potential dutasteride-related systemic adverse effects cannot be excluded simply because the formulation is topical or lower concentration. Current UK dutasteride safety advice remains relevant.
How long does 0.02% topical dutasteride take to work?
The Phase II trial assessed treatment over 24 weeks. Hair-loss treatment generally requires several months before response can be meaningfully assessed.
Do I need a prescription for topical dutasteride in the UK?
Yes. Dutasteride is a prescription-only medicine and requires appropriate clinical assessment before supply.
Can I get personalised 0.02% topical dutasteride online in the UK?
Root & Radiance provides a Hair Customiser where personalised topical hair-loss options and strengths can be explored. Prescription-only treatment is supplied only where clinically appropriate following prescriber review.
Evidence and Further Reading
- Panuganti VK et al. A Randomized, Double-Blind, Placebo and Active Controlled Phase II Study to Evaluate the Safety and Efficacy of Novel Dutasteride Topical Solution (0.01%, 0.02%, and 0.05% w/v) in Male Subjects With Androgenetic Alopecia. Cureus. 2025. PubMed
- Andrade JFM et al. Topical dutasteride for androgenic alopecia: current state and prospects. Therapeutic Delivery. 2025. PubMed
- Medicines and Healthcare products Regulatory Agency. Finasteride and Dutasteride: updated safety warnings for psychiatric side effects and sexual dysfunction. May 2026. MHRA